CV Sciences Appoints New Chief Medical Officer
Ticker: CVSI · Form: 8-K · Filed: Jun 25, 2024 · CIK: 1510964
| Field | Detail |
|---|---|
| Company | Cv Sciences, Inc. (CVSI) |
| Form Type | 8-K |
| Filed Date | Jun 25, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 9 min |
| Key Dollar Amounts | $300,000, $235,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel, biotech
TL;DR
CV Sciences just hired a new CMO to push their drug pipeline forward.
AI Summary
CV Sciences, Inc. announced on June 20, 2024, the appointment of Dr. Michael L. Smith as Chief Medical Officer. Dr. Smith brings extensive experience in pharmaceutical development and medical affairs, previously holding leadership roles at various biopharmaceutical companies. This appointment is part of the company's strategy to advance its drug development pipeline.
Why It Matters
The appointment of a new Chief Medical Officer signals a strategic move by CV Sciences to bolster its leadership in drug development, potentially accelerating its pipeline and future product launches.
Risk Assessment
Risk Level: medium — The appointment of a new executive, especially to a critical role like CMO, carries inherent risks related to integration, strategic alignment, and the individual's effectiveness in driving the company's objectives.
Key Players & Entities
- CV Sciences, Inc. (company) — The company filing the report.
- Dr. Michael L. Smith (person) — Newly appointed Chief Medical Officer.
- June 20, 2024 (date) — Date of the earliest event reported.
FAQ
What is the effective date of Dr. Michael L. Smith's appointment as Chief Medical Officer?
The report indicates the earliest event reported was on June 20, 2024, which is when the appointment would have become effective or was announced.
What is CV Sciences, Inc.'s primary business sector?
CV Sciences, Inc. is in the Pharmaceutical Preparations sector, with SIC code 2834.
Where is CV Sciences, Inc. headquartered?
The company's principal executive offices are located at 9530 Padgett Street, Suite 107, San Diego, California 92126.
Has CV Sciences, Inc. undergone any previous name changes?
Yes, the company was formerly known as CannaVEST Corp. (name change effective February 5, 2013) and Foreclosure Solutions, Inc. (name change effective January 24, 2011).
What is the SEC file number for CV Sciences, Inc.?
The SEC file number for CV Sciences, Inc. is 000-54677.
Filing Stats: 2,171 words · 9 min read · ~7 pages · Grade level 12.1 · Accepted 2024-06-24 18:25:48
Key Financial Figures
- $300,000 — d provides for an annual base salary of $300,000 (the "Base Salary"), which amount shall
- $235,000 — d provides for an annual base salary of $235,000 (the "CFO Base Salary"), which amount s
Filing Documents
- cvsi-20240620.htm (8-K) — 59KB
- cvsi-ex10_1.htm (EX-10.1) — 157KB
- cvsi-ex10_2.htm (EX-10.2) — 128KB
- 0000950170-24-076955.txt ( ) — 445KB
- cvsi-20240620.xsd (EX-101.SCH) — 22KB
- cvsi-20240620_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 10.1 Executive Employment Agreement, dated June 20, 2024, by and between CV Sciences, Inc. and Joseph Dowling 10.2 Executive Employment Agreement, dated June 20, 2024, by and between CV Sciences, Inc. and Joerg Grasser 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CV SCIENCES, INC. Date: June 24, 2024 By: /s/ Joseph Dowling Joseph Dowling Chief Executive Officer 4